Australia - English - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - pomalidomide, quantity: 1 mg - capsule, hard - excipient ingredients: crospovidone; maltodextrin; carmoisine; sodium stearylfumarate; gelatin; pregelatinised maize starch; patent blue v; colloidal anhydrous silica; brilliant blue fcf; titanium dioxide; iron oxide yellow; brilliant black bn; iron oxide black - pomalidomide medicianz, in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior treatment regimen including lenalidomide.,pomalidomide medicianz, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - pomalidomide, quantity: 1 mg - capsule, hard - excipient ingredients: crospovidone; colloidal anhydrous silica; iron oxide yellow; maltodextrin; brilliant blue fcf; gelatin; pregelatinised maize starch; titanium dioxide; patent blue v; carmoisine; brilliant black bn; iron oxide black; sodium stearylfumarate - pomalidomide medsurge, in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior treatment regimen including lenalidomide.,pomalidomide medsurge, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.

Canada - English - Health Canada

natco pharma (canada) inc - pomalidomide - capsule - 1mg - pomalidomide 1mg

Canada - English - Health Canada

natco pharma (canada) inc - pomalidomide - capsule - 2mg - pomalidomide 2mg

Canada - English - Health Canada

natco pharma (canada) inc - pomalidomide - capsule - 3mg - pomalidomide 3mg

Canada - English - Health Canada

natco pharma (canada) inc - pomalidomide - capsule - 4mg - pomalidomide 4mg

United States - English - NLM (National Library of Medicine)

celgene corporation - pomalidomide (unii: d2ux06xlb5) (pomalidomide - unii:d2ux06xlb5) - pomalidomide 1 mg - pomalyst, in combination with dexamethasone, is indicated for adult patients with multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy. pomalyst is indicated for the treatment of: this indication is approved under accelerated approval based on overall response rate [see clinical studies (14.2)] . continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). pomalyst is contraindicated in females who are pregnant. pomalyst can cause fetal harm when administered to a pregnant female [see warnings and precautions (5.1) and use in specific populations (8.1)]. pomalidomide is a thalidomide analogue and is teratogenic in both rats and rabbits when administered during the period of organogenesis. if the patient becomes pregnant while taking this drug, the patient should be appris

European Union - English - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - pomalidomide - multiple myeloma - immunosuppressants - imnovid in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide.imnovid in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

celgene pty ltd - pomalidomide, quantity: 1 mg - capsule - excipient ingredients: sodium stearylfumarate; mannitol; pregelatinised maize starch; titanium dioxide; indigo carmine; iron oxide yellow; shellac; simethicone; propylene glycol; strong ammonia solution; isopropyl alcohol; butan-1-ol; ethanol absolute; iron oxide black; gelatin - pomalyst, in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior treatment regimen including lenalidomide. pomalyst, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

celgene pty ltd - pomalidomide, quantity: 3 mg - capsule - excipient ingredients: pregelatinised maize starch; mannitol; sodium stearylfumarate; iron oxide black; shellac; propylene glycol; strong ammonia solution; ethanol absolute; purified water; butan-1-ol; isopropyl alcohol; indigo carmine; iron oxide yellow; titanium dioxide; gelatin - pomalyst, in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior treatment regimen including lenalidomide. pomalyst, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.